(RTTNews) - Pfizer Inc. (PFE) announced Friday that the U.S. Food and Drug Administration has approved HYMPAVZI (marstacimab-hncq) for routine prophylaxis to prevent or reduce the frequency of ...
The summary covers major health news, including six transplant patients in Brazil contracting HIV from infected organs, ...
The cost of healthcare in the U.S. remains outrageously high, despite massive government subsidies. The system is designed to ...
The Pharmacy Shop in Lexington offers walk-in vaccines. Pharmacy owner and Pharmacist Clarence Sullivan says he encourages ...
The FDA approved Pfizer’s Hympavzi (marstacimab-hncq) to prevent or reduce the frequency of bleeding episodes in patients age ...
An agriculture conglomerate and a related company settled a lawsuit with Los Angeles for $35 million over the sale of ...
The U.S. Food and Drug Administration on Friday agreed to reconsider its recent decision barring drug compounders from ...
Recent health developments include HIV infections from organ transplants in Brazil, Sanofi's potential sale of a stake in its ...
The FDA approved marstacimab (Hympavzi) for routine prophylaxis to prevent or reduce bleeding episodes in adults and ...
Genentech Inc. didn’t need to wait until Thanksgiving for the U.S. FDA to make up its mind. More than a month ahead of its ...
The monoclonal antibody is the first non-factor, once-weekly treatment approved in the United States for hemophilia B.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback